David Lowrance Sells Shares of SVRA $SVRA
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
David Lowrance, Chief Financial Officer at Savara Inc. ($SVRA), sold 185,659 shares at an average price of $5.50, for a total transaction of $1.02 million. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Savara Inc. Stock Up 8.2%
Shares of Savara Inc. ($SVRA) traded around $5.69 on Tuesday, up 8.2% for the day.
Savara Inc. Earnings
Analysts Set New Price Targets
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Get Savara Inc. alerts
New 13F filings, insider trades, and analyst moves on $SVRA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.